Heterodimeric Barnase-Barstar Vaccine Molecules: Influence of One versus Two Targeting Units Specific for Antigen Presenting Cells

PLoS ONE

Volumn 7, Issue 9, 2012, Pages

  Spång, Heidi Cecilie Larsen ^a   Braathen, Ranveig ^a   Bogen, Bjarne ^a  

^a UNIVERSITY OF OSLO   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

BARNASE; BARSTAR; DNA VACCINE; FLUORESCENT DYE; IMMUNOGLOBULIN G1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MCHERRY; PARAPROTEIN; PROTEIN M315; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANTIGEN PRESENTING CELL; ARTICLE; CARBOXY TERMINAL SEQUENCE; CD4+ T LYMPHOCYTE; CELL STRAIN HEK293; COMPLEX FORMATION; CONTROLLED STUDY; DIMERIZATION; DNA IMMUNIZATION; FEMALE; HUMORAL IMMUNITY; IN VITRO STUDY; IN VIVO STUDY; MOLECULAR CLONING; MOLECULAR INTERACTION; MOUSE; NONHUMAN;

ANIMALS; ANTIGEN-PRESENTING CELLS; BACTERIAL PROTEINS; BLOTTING, WESTERN; CELL LINE; ELECTROPHORESIS, POLYACRYLAMIDE GEL; ELECTROPORATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HUMANS; MICE; MICE, INBRED BALB C; MICE, TRANSGENIC; PROTEIN MULTIMERIZATION; RECOMBINANT FUSION PROTEINS; RIBONUCLEASES; T-LYMPHOCYTES; VACCINES, DNA;

BACTERIA (MICROORGANISMS);

EID: 84866518210     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0045393     Document Type: Article

References (48)

1. Liu MA, (2011) DNA vaccines: an historical perspective and view to the future. Immunol Rev 239: 62-84.
2. Bergman PJ, McKnight J, Novosad A, Charney S, Farrelly J, et al. (2003) Long-term survival of dogs with advanced malignant melanoma after DNA vaccination with xenogeneic human tyrosinase: a phase I trial. Clin Cancer Res 9: 1284-1290.
3. Liao JC, Gregor P, Wolchok JD, Orlandi F, Craft D, et al. (2006) Vaccination with human tyrosinase DNA induces antibody responses in dogs with advanced melanoma. Cancer Immun 6: 8.
4. Davis BS, Chang GJ, Cropp B, Roehrig JT, Martin DA, et al. (2001) West Nile virus recombinant DNA vaccine protects mouse and horse from virus challenge and expresses in vitro a noninfectious recombinant antigen that can be used in enzyme-linked immunosorbent assays. J Virol 75: 4040-4047.
5. Ulmer JB, Wahren B, Liu MA, (2006) Gene-based vaccines: recent technical and clinical advances. Trends Mol Med 12: 216-222.
6. Widera G, Austin M, Rabussay D, Goldbeck C, Barnett SW, et al. (2000) Increased DNA vaccine delivery and immunogenicity by electroporation in vivo. J Immunol 164: 4635-4640.
7. Tollefsen S, Vordermeier M, Olsen I, Storset AK, Reitan LJ, et al. (2003) DNA injection in combination with electroporation: a novel method for vaccination of farmed ruminants. Scand J Immunol 57: 229-238.
8. Tjelle TE, Corthay A, Lunde E, Sandlie I, Michaelsen TE, et al. (2004) Monoclonal antibodies produced by muscle after plasmid injection and electroporation. Mol Ther 9: 328-336.
9. Wang S, Farfan-Arribas DJ, Shen S, Chou TH, Hirsch A, et al. (2006) Relative contributions of codon usage, promoter efficiency and leader sequence to the antigen expression and immunogenicity of HIV-1 Env DNA vaccine. Vaccine 24: 4531-4540.
10. Kawamura H, Berzofsky JA, (1986) Enhancement of antigenic potency in vitro and immunogenicity in vivo by coupling the antigen to anti-immunoglobulin. J Immunol 136: 58-65.
11. Snider DP, Segal DM, (1987) Targeted antigen presentation using crosslinked antibody heteroaggregates. J Immunol 139: 1609-1616.
12. Castro FV, Tutt AL, White AL, Teeling JL, James S, et al. (2008) CD11c provides an effective immunotarget for the generation of both CD4 and CD8 T cell responses. Eur J Immunol 38: 2263-2273.
13. Baier G, Baier-Bitterlich G, Looney DJ, Altman A, (1995) Immunogenic targeting of recombinant peptide vaccines to human antigen-presenting cells by chimeric anti-HLA-DR and anti-surface immunoglobulin D antibody Fab fragments in vitro. J Virol 69: 2357-2365.
14. Guyre PM, Graziano RF, Goldstein J, Wallace PK, Morganelli PM, et al. (1997) Increased potency of Fc-receptor-targeted antigens. Cancer Immunol Immunother 45: 146-148.
15. Lunde E, Munthe LA, Vabo A, Sandlie I, Bogen B, (1999) Antibodies engineered with IgD specificity efficiently deliver integrated T-cell epitopes for antigen presentation by B cells. Nat Biotechnol 17: 670-675.
16. Hawiger D, Inaba K, Dorsett Y, Guo M, Mahnke K, et al. (2001) Dendritic cells induce peripheral T cell unresponsiveness under steady state conditions in vivo. J Exp Med 194: 769-779.
17. Ruffini PA, Biragyn A, Coscia M, Harvey LK, Cha SC, et al. (2004) Genetic fusions with viral chemokines target delivery of nonimmunogenic antigen to trigger antitumor immunity independent of chemotaxis. J Leukoc Biol 76: 77-85.
18. Demangel C, Zhou J, Choo AB, Shoebridge G, Halliday GM, et al. (2005) Single chain antibody fragments for the selective targeting of antigens to dendritic cells. Mol Immunol 42: 979-985.
19. Fredriksen AB, Sandlie I, Bogen B, (2006) DNA vaccines increase immunogenicity of idiotypic tumor antigen by targeting novel fusion proteins to antigen-presenting cells. Mol Ther 13: 776-785.
20. Schjetne KW, Fredriksen AB, Bogen B, (2007) Delivery of antigen to CD40 induces protective immune responses against tumors. J Immunol 178: 4169-4176.
21. Nchinda G, Kuroiwa J, Oks M, Trumpfheller C, Park CG, et al. (2008) The efficacy of DNA vaccination is enhanced in mice by targeting the encoded protein to dendritic cells. J Clin Invest 118: 1427-1436.
22. Fredriksen AB, Bogen B, (2007) Chemokine-idiotype fusion DNA vaccines are potentiated by bivalency and xenogeneic sequences. Blood 110: 1797-1805.
23. Deyev SM, Waibel R, Lebedenko EN, Schubiger AP, Pluckthun A, (2003) Design of multivalent complexes using the barnase*barstar module. Nat Biotechnol 21: 1486-1492.
24. Hartley RW, (1989) Barnase and barstar: two small proteins to fold and fit together. Trends Biochem Sci 14: 450-454.
25. Hartley RW, (2001) Barnase-barstar interaction. Methods Enzymol 341: 599-611.
26. Green NM, (1990) Avidin and streptavidin. Methods Enzymol 184: 51-67.
27. Guillet V, Lapthorn A, Hartley RW, Mauguen Y, (1993) Recognition between a bacterial ribonuclease, barnase, and its natural inhibitor, barstar. Structure 1: 165-176.
28. Buckle AM, Schreiber G, Fersht AR, (1994) Protein-protein recognition: crystal structural analysis of a barnase-barstar complex at 2.0-A resolution. Biochemistry 33: 8878-8889.
29. Nikitin MP, Zdobnova TA, Lukash SV, Stremovskiy OA, Deyev SM, (2010) Protein-assisted self-assembly of multifunctional nanoparticles. Proc Natl Acad Sci U S A 107: 5827-5832.
30. Semenyuk EG, Stremovskiy OA, Edelweiss EF, Shirshikova OV, Balandin TG, et al. (2007) Expression of single-chain antibody-barstar fusion in plants. Biochimie 89: 31-38.
31. Glinka EM, Edelweiss EF, Sapozhnikov AM, Deyev SM, (2006) A new vector for controllable expression of an anti-HER2/neu mini-antibody-barnase fusion protein in HEK 293T cells. Gene 366: 97-103.
32. Shaner NC, Campbell RE, Steinbach PA, Giepmans BN, Palmer AE, et al. (2004) Improved monomeric red, orange and yellow fluorescent proteins derived from Discosoma sp. red fluorescent protein. Nat Biotechnol 22: 1567-1572.
33. Oynebraten I, Lovas TO, Thompson K, Bogen B, (2012) Generation of antibody-producing hybridomas following one single immunization with a targeted DNA vaccine. Scand J Immunol 75: 379-388.
34. Bogen B, Gleditsch L, Weiss S, Dembic Z, (1992) Weak positive selection of transgenic T cell receptor-bearing thymocytes: importance of major histocompatibility complex class II, T cell receptor and CD4 surface molecule densities. Eur J Immunol 22: 703-709.
35. Kim KJ, Kanellopoulos-Langevin C, Merwin RM, Sachs DH, Asofsky R, (1979) Establishment and characterization of BALB/c lymphoma lines with B cell properties. J Immunol 122: 549-554.
36. Bogen B, Malissen B, Haas W, (1986) Idiotope-specific T cell clones that recognize syngeneic immunoglobulin fragments in the context of class II molecules. Eur J Immunol 16: 1373-1378.
37. Oynebraten I, Lovas TO, Thompson K, Bogen B (2011) Generation of antibody-producing hybridomas following one single immunization with a targeted DNA vaccine. Scand J Immunol.
38. Lunde E, Western KH, Rasmussen IB, Sandlie I, Bogen B, (2002) Efficient delivery of T cell epitopes to APC by use of MHC class II-specific troybodies. Journal of Immunology 168: 2154-2162.
39. Roos AK, Eriksson F, Walters DC, Pisa P, King AD, (2009) Optimization of Skin Electroporation in Mice to Increase Tolerability of DNA Vaccine Delivery to Patients. Molecular Therapy 17: 1637-1642.
40. Lunde E, Western KH, Rasmussen IB, Sandlie I, Bogen B, (2002) Efficient delivery of T cell epitopes to APC by use of MHC class II-specific Troybodies. J Immunol 168: 2154-2162.
41. Hartley RW, (1993) Directed mutagenesis and barnase-barstar recognition. Biochemistry 32: 5978-5984.
42. Bogen B, Lambris JD, (1989) Minimum length of an idiotypic peptide and a model for its binding to a major histocompatibility complex class II molecule. EMBO J 8: 1947-1952.
43. Bogen B, Snodgrass R, Briand JP, Hannestad K, (1986) Synthetic peptides and beta-chain gene rearrangements reveal a diversified T cell repertoire for a lambda light chain third hypervariable region. Eur J Immunol 16: 1379-1384.
44. Roos AK, Moreno S, Leder C, Pavlenko M, King A, et al. (2006) Enhancement of cellular immune response to a prostate cancer DNA vaccine by intradermal electroporation. Mol Ther 13: 320-327.
45. Sirisinha S, Eisen HN, (1971) Autoimmune-like antibodies to the ligand-binding sites of myeloma proteins. Proc Natl Acad Sci U S A 68: 3130-3135.
46. Dormitzer PR, Ulmer JB, Rappuoli R, (2008) Structure-based antigen design: a strategy for next generation vaccines. Trends Biotechnol 26: 659-667.
47. Ruffini PA, Grodeland G, Fredriksen AB, Bogen B, (2010) Human chemokine MIP1alpha increases efficiency of targeted DNA fusion vaccines. Vaccine 29: 191-199.
48. Roos AK, Eriksson F, Timmons JA, Gerhardt J, Nyman U, et al. (2009) Skin electroporation: effects on transgene expression, DNA persistence and local tissue environment. PLoS One 4: e7226.